Literature DB >> 32058069

GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables.

Holger J Schünemann1, Reem A Mustafa2, Jan Brozek3, Karen R Steingart4, Mariska Leeflang5, Mohammad Hassan Murad6, Patrick Bossuyt5, Paul Glasziou7, Roman Jaeschke3, Stefan Lange8, Joerg Meerpohl9, Miranda Langendam5, Monica Hultcrantz10, Gunn E Vist11, Elie A Akl12, Mark Helfand13, Nancy Santesso3, Lotty Hooft14, Rob Scholten14, Måns Rosen10, Anne Rutjes15, Mark Crowther3, Paola Muti16, Heike Raatz17, Mohammed T Ansari18, John Williams19, Regina Kunz20, Jeff Harris21, Ingrid Arévalo Rodriguez22, Mikashmi Kohli23, Gordon H Guyatt24.   

Abstract

OBJECTIVES: This article provides updated GRADE guidance about how authors of systematic reviews and health technology assessments and guideline developers can rate the certainty of evidence (also known as quality of the evidence or confidence in the estimates) of a body of evidence addressing test accuracy (TA) on the domains imprecision, inconsistency, publication bias, and other domains. It also provides guidance for how to present synthesized information in evidence profiles and summary of findings tables. STUDY DESIGN AND
SETTING: We present guidance for rating certainty in TA in clinical and public health and review the presentation of results of a body of evidence regarding tests.
RESULTS: Supplemented by practical examples, we describe how raters of the evidence can apply the GRADE domains inconsistency, imprecision, and publication bias to a body of evidence of TA studies.
CONCLUSION: Using GRADE in Cochrane and other reviews as well as World Health Organization and other guidelines helped refining the GRADE approach for rating the certainty of a body of evidence from TA studies. Although several of the GRADE domains (e.g., imprecision and magnitude of the association) require further methodological research to help operationalize them, judgments need to be made on the basis of what is known so far.
Copyright © 2020 Elsevier Inc. All rights reserved.

Keywords:  Certainty of evidence; Diagnosis; Diagnostic accuracy; GRADE; Guidelines; HTA; Systematic reviews; Test accuracy; Tests

Year:  2020        PMID: 32058069     DOI: 10.1016/j.jclinepi.2019.12.021

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  51 in total

Review 1.  Diagnostic performance of apparent diffusion coefficient (ADC) for differentiating endometrial carcinoma from benign lesions: a systematic review and meta-analysis.

Authors:  Yashar Moharamzad; Amir H Davarpanah; Ali Yaghobi Joybari; Fatemeh Shahbazi; Leila Esmaeilian Toosi; Melika Kooshkiforooshani; Ali Ansari; Morteza Sanei Taheri
Journal:  Abdom Radiol (NY)       Date:  2020-09-15

2.  A user guide to the American Society of Hematology clinical practice guidelines.

Authors:  Ariel Izcovich; Adam Cuker; Robert Kunkle; Ignacio Neumann; Julie Panepinto; Menaka Pai; Matthew Seftel; Matthew C Cheung; Richard Lottenberg; Michael Byrne; Robert Plovnick; Deirdra Terrell; Jennifer L Holter-Chakrabarty; Benjamin Djulbegovic; Lisa K Hicks; Wojtek Wiercioch; Robby Nieuwlaat; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-05-12

3.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

4.  Can gray values be converted to Hounsfield units? A systematic review.

Authors:  Marjorie Eguren; Anderson Holguin; Karla Diaz; Jose Vidalon; Carlos Linan; Camila Pacheco-Pereira; Manuel Oscar Lagravere Vich
Journal:  Dentomaxillofac Radiol       Date:  2021-06-19       Impact factor: 2.419

5.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

6.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

7.  Ultrasound for the diagnosis of malrotation and volvulus in children and adolescents: a systematic review and meta-analysis.

Authors:  HaiThuy N Nguyen; Madhulika Kulkarni; Jisha Jose; Amy Sisson; Mary L Brandt; Marla B K Sammer; Mohan Pammi
Journal:  Arch Dis Child       Date:  2021-04-20       Impact factor: 3.791

8.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

9.  Ultrasound for diagnosis of birth weight discordance in twin pregnancies.

Authors:  Shayesteh Jahanfar; Jacqueline J Ho; Sharifah Halimah Jaafar; Iosief Abraha; Mohaddesseh Noura; Cassandra R Ross; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09

10.  Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Authors:  Kamal Awad; Maged Mohammed; Mahmoud Mohamed Zaki; Abdelrahman I Abushouk; Gregory Y H Lip; Michael J Blaha; Carl J Lavie; Peter P Toth; J Wouter Jukema; Naveed Sattar; Maciej Banach
Journal:  BMC Med       Date:  2021-06-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.